-
公开(公告)号：US12233121B2
公开(公告)日：2025-02-25
申请号：US17938454
申请日：2022-10-06
Inventor： Jeroen Geurtsen , Pieter Jan Burghout , Eveline Marleen Weerdenburg , Jan Theunis Poolman , Kellen Cristhina Fae , Patricia Ibarra Yon , Darren Robert Abbanat , Stefan Jochen Kemmler , Michael Thomas Kowarik , Manuela Mally , Veronica Gambillara Fonck , Martin Edward Braun , Maria Paula Carranza Sandmeier
IPC: A61K39/108 , A61K39/00 , A61K39/02 , A61K39/085 , A61K39/09 , A61K39/095 , A61K39/102 , A61K39/104 , A61K47/64
Abstract: Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).
-
公开(公告)号：US12186333B2
公开(公告)日：2025-01-07
申请号：US18333591
申请日：2023-06-13
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Andrew Geall , Katrin Ramsauer , Gillis Otten , Christian Walter Mandl
IPC: A61K39/09 , A61K31/7088 , A61K39/00 , A61K39/12
Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.
-
公开(公告)号：US20240382585A1
公开(公告)日：2024-11-21
申请号：US18742842
申请日：2024-06-13
Inventor： Brendan WREN , Jeremy BROWN , Jon CUCCUI
IPC: A61K39/385 , A61K39/00 , A61K39/09 , A61K47/64 , A61P31/04 , C07K14/315
Abstract: This invention relates to the use of S. pneumoniae protein antigens, such as NanA, PluA and Sp0148, as carriers for immunogenic S. pneumoniae capsular polysaccharide. This may be useful for example in glycoconjugate vaccines able to generate a protective immune response against multiple capsuler serotypes. Glycoconjugates, vaccine compositions and methods of manufacture and use are provided.
-
公开(公告)号：US20240358823A1
公开(公告)日：2024-10-31
申请号：US18434318
申请日：2024-02-06
Applicant: Vaxcyte, Inc.
Inventor： Jeffery C. FAIRMAN , Jon H. HEINRICHS , Wei CHAN
IPC: A61K39/385 , A61K38/00 , A61K39/00 , A61K39/09 , A61P31/04 , C07K14/00 , C07K14/285 , C07K14/33 , C07K14/34
CPC classification number: A61K39/385 , A61K39/092 , A61P31/04 , C07K14/001 , C07K14/285 , C07K14/33 , C07K14/34 , A61K38/00 , A61K2039/6037 , A61K2039/627 , A61K2039/70
Abstract: Methods for the production of immunogenic compositions containing a non-natural amino acid are disclosed. The non-natural amino acid can be a site for attachment of antigens, such as bacterial capsular polysaccharides, to make immunogenic conjugates. Bio-orthogonal attachment chemistry incorporated into the non-natural amino acids allows for more efficient and potent antigen presentation to the immune system, simplified purification, and more well-defined structure of these semi-synthetic immunogens.
-
公开(公告)号：US20240325514A1
公开(公告)日：2024-10-03
申请号：US18293380
申请日：2022-06-29
Applicant: Intervet Inc.
Inventor： Antonius Arnoldus Christiaan Jacobs
CPC classification number: A61K39/092 , A61P37/04 , A61K2039/552
Abstract: The present invention pertains to a vaccine for protection against a pathogenic infection with Streptococcus suis, the vaccine comprising a whole IgM protease antigen of Streptococcus suis, the antigen comprising in its amino acid sequence less than four repeats, and a pharmaceutically acceptable carrier. The invention also pertains to this antigen for use in a method to protect a pig against such an infection, and to a method to protect such a pig.
-
Patent Agency Ranking
公开(公告)号：US12097250B2
公开(公告)日：2024-09-24
申请号：US18505504
申请日：2023-11-09
Applicant: Merck Sharp & Dohme LLC
Inventor： William J. Smith , Patrick McHugh , Michael Albert Winters , Julie M. Skinner , Jian He , Luwy Musey , Chitrananda Abeygunawardana , Yadong Adam Cui , Michael J. Kosinski
IPC: A61K39/00 , A61K39/09 , A61K39/116 , A61K39/145 , A61K39/385 , A61K47/02 , A61K47/10 , A61K47/22 , A61P31/04 , A61K9/00
CPC classification number: A61K39/092 , A61K39/116 , A61K39/145 , A61K39/385 , A61K47/02 , A61K47/10 , A61K47/22 , A61P31/04 , A61K9/0019 , A61K2039/54 , A61K2039/545 , A61K2039/55 , A61K2039/55516 , A61K2039/6037 , A61K2039/70
Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.
-
7.发明授权公开(公告)号：US12083173B2
公开(公告)日：2024-09-10
申请号：US17834865
申请日：2022-06-07
Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
Inventor： Richard Malley , Yingjie Lu , Fan Zhang
IPC: A61K39/09 , A61K39/00 , C07K14/315
CPC classification number: A61K39/092 , C07K14/3156 , A61K2039/55505 , A61K2039/6087 , A61K2039/625 , Y02A50/30
Abstract: The present application is generally directed to novel pneumococcal polypeptide antigens and nucleic acids encoding such antigens, and immunogenic compositions comprising such antigens for treating and preventing pneumococcal infection. The present invention further provides method of using the antigens to elicits an immune response (e.g., IL-17A response, a T cell-mediated and/or B-cell-mediated immune responses). The present invention also provides methods of prophylaxis and/or treatment of pneumococcal-mediated diseases, such as sepsis, comprising administering an immunogenic composition including one or more of a combination of pneumococcal antigens or functional fragments thereof as disclosed herein. In some embodiments, one or more pneumococcal antigens can be present in a polysaccharide conjugate. The compositions induce an anti-pneumococcus immune response when administered to a mammal. The compositions can be used prophylactically to vaccinate an individual and/or therapeutically to induce a therapeutic immune response to an infected individual.
-
公开(公告)号：US12036275B2
公开(公告)日：2024-07-16
申请号：US16985589
申请日：2020-08-05
Applicant: Ceva Santé Animale S.A.
Inventor： Jana Seele , Christoph Baums , Peter Valentin-Weigand
CPC classification number: A61K39/092 , C07K16/1275 , A61K2039/53 , A61K2039/54 , A61K2039/543 , A61K2039/545 , A61K2039/552 , A61K2039/575
Abstract: Described is a vaccine composition comprising an effective amount of at least one polypeptide selected from the group of IdeSsuis, rIdeSsuis, an analogue or a fragment thereof, or a polynucleotide encoding the same. This vaccine composition is used in the prophylactic, metaphylactic or therapeutic treatment of a Streptococcus suis infections in pigs or humans.
-
公开(公告)号：US20240216496A1
公开(公告)日：2024-07-04
申请号：US18330968
申请日：2023-06-07
Applicant: Taichung Veterans General Hospital
Inventor： Mey Fann LEE , Yi-Hsing CHEN
CPC classification number: A61K39/09 , A61K35/74 , A61P11/06 , A61P17/00 , A61P37/08 , C12N1/20 , C12N15/746 , C12N2800/101
Abstract: A recombinant lactic acid bacterium and a method thereof for simultaneous treatment and/or prevention of dust mite and cockroach allergies. The recombinant lactic acid bacterium has a gene fragment with nucleotide coded as SEQ ID No: 1 to be capable of expressing the D2P2 protein with amino acid sequence of SEQ ID No: 2. Therefore, by administering an effective amount of the recombinant lactic acid bacterium to an individual is capable of effectively causing the individual's body to produce antibodies against dust mite and/or cockroach allergens, thereby achieving an efficacy of preventing and/or treating an allergic disease caused by dust mite and/or cockroach allergens.
-
公开(公告)号：US20240197851A1
公开(公告)日：2024-06-20
申请号：US17909917
申请日：2021-03-12
Applicant: Intervet Inc.
Inventor： Antonius Arnoldus Christiaan Jacobs
CPC classification number: A61K39/092 , A61P31/04 , A61P37/04 , A61K2039/552 , A61K2039/70
Abstract: The present invention pertains to a vaccine comprising in combination an IgM protease antigen of Streptococcus suis and a Streptococcus suis bacterin of serotype (9), sequence type (16), for use in a method for protecting pigs against a pathogenic infection with Streptococcus suis serotype (9), sequence type (16).
-
-
-
-
-
-
-
-
-
Search Results
1736
records
(took 0.03 seconds)
